Alternative tumor markers in the diagnosis of ovarian cancer

Karakaya, Burcu Kisa; Başer, Eralp; Bildaci, Berk; Cömert, Esra Çabuk; Bayraktar, Nilüfer; Dursun, Polat; Kuşçu, Esra; Ayhan, Ali̇

doi:10.5603/gp.2016.0045

Cited by 8 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, early detection could prove important to improve the outcome and survival rate of women affected with ovarian cancer. In a recent study by, 45 it is established that serum CA125, serum HE4 and urine HE4 levels were increased in patients with ovarian cancer. But the changes occur in molecular levels, thus suggesting that the marker should also be established in the DNA level.…”

Section: Key Aspects Of Mtdna As a Diagnostic Marker In Ovarian Cancermentioning

confidence: 98%

An overview about mitochondrial DNA mutations in ovarian cancer

Iyer

Santhy²

2017

Alexandria Journal of Medicine

View full text Add to dashboard Cite

Background: Ovarian tumour is the second most common form of cancer affecting female reproductive system and the most lethal of the gynaecological malignancies. Since past decades, tremendous efforts have been made to illuminate the molecular basis for initiation and progression of ovarian carcinoma. A low quantity of dysfunction in mitochondrial DNA (mtDNA) is considered to be a risk factor for variety of cancer types. Mitochondrial dysfunctions have been allied with varied metabolic diseases and for occurrence of cancer. Researches say that mtDNA have pivotal role in development of cancer but future work has to be carried out to know the exact significance of specific mitochondrial mutations linked with cancer and disease progression. Most of mtDNA mutations in gynecological cancers are observed in the D-loop region. Objective: This review article provides a detailed summary about the ovarian cancer and mutations observed in mtDNA. Result: Furthermore, this review offers some perspective as to the mtDNA origin of these mutations in ovarian cancer, their functional consequences in ovarian cancer development, to check for incidence rate for transmission of the disease through maternal lineages and possible diagnostic marker implication.

show abstract

Section: Key Aspects Of Mtdna As a Diagnostic Marker In Ovarian Cancermentioning

confidence: 98%

An overview about mitochondrial DNA mutations in ovarian cancer

Iyer

Santhy²

2017

Alexandria Journal of Medicine

View full text Add to dashboard Cite

show abstract

“…Targeting only endothelial cells has no effect on tumor cells that are involved in VM network formation. Therefore, there is a strong clinical need to develop new ways of targeted antivascular modalities which would be based not only on cancer stage but also on a type of its vascularization [31,32]. Moreover, specific inhibitors to these molecular mechanisms that control specific microvascular network need to be developed.…”

Section: Discussionmentioning

confidence: 99%

Mig-7 expression and vasculogenic mimicry in malignant ovarian tumors

Czekierdowski

Czekierdowska

Stachowicz³

et al. 2017

Ginekol Pol

View full text Add to dashboard Cite

Objectives:To investigate the possible association of vasculogenic mimicry (VM), VE-cadherin and MIG-7 expression with clinicopathological features of women with malignant ovarian masses. Material and methods:VM was studied with the PAS reaction and VE-cadherin was assessed with immunohistochemistry in 108 women with malignant ovarian tumors. Additionally, quantitative expression of MIG-7 mRNA was performed in 52 ovarian cancers with qRT-PCR.Results: VM was found in 48/108 cases (44%), more often in higher FIGO stage tumors (83% cases; 40 vs. 8; p = 0.01). High expression of VE-cadherin was present in 37% of all ovarian masses. Ovarian tumors without VM more often expressed low levels of VE-cadherin than tumors where VM was found (37.6% vs.14.6%). No expression or very low expression of MIG-7 mRNA was found in all normal ovarian tissues and in 32 cancer samples. Median RQ of MIG-7 mRNA in tumor samples was higher than in normal ovarian tissue (RQ = 0.29 vs. RQ = 0.05, respectively; p < 0.005) and higher than in non-malignant ovarian masses (0.98 vs. 0.05 respectively; p = 0.03). Expression of MIG-7 mRNA was significantly correlated with VM (p = 0.039). In tumors with PAS-positive structures median RQ MIG-7 mRNA was higher than in tumors with PAS-negative findings (1.89 vs. 0.13 respectively). VE-cadherin expression was more frequently found in tumors where MIG-7 mRNA was present (p = 0.004). Conclusions:Vasculogenic mimicry exists in malignant ovarian tumors and advanced clinical stages of malignancy are accompanied by a high incidence of VM formation. MIG-7 mRNA and VE-cadherin expression may serve as additional molecular markers of VM in ovarian malignancies.

show abstract

“…The vast majority of the ovarian OC deaths are related to advanced clinical stages of high-grade serous ovarian cancer (HGSOC) [ 4 ]. HGSOC is type II epithelial OC and is characterized by high malignity, aggressive spread with extreme sensitivity and resistance to chemotherapy [ 5 , 6 , 7 , 8 ]. There are five molecular subtypes of HGSOC: mesenchymal, anti-mesenchymal, differentiated, proliferative, and immunoreactive [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer

Al‐Dossary

Tawfik

Isichei

et al. 2021

Cancers

View full text Add to dashboard Cite

High-grade serous ovarian cancer (HGSOC) is the most lethal gynecological malignancy among women. Several obstacles impede the early diagnosis and effective treatment options for ovarian cancer (OC) patients, which most importantly include the development of platinum-drug-resistant strains. Currently, extensive efforts are being put into the development of strategies capable of effectively circumventing the physical and biological barriers present in the peritoneal cavity of metastatic OC patients, representing a late stage of gastrointestinal and gynecological cancer with an extremely poor prognosis. Naturally occurring extracellular vesicles (EVs) have been shown to play a pivotal role in progression of OC and are now being harnessed as a delivery vehicle for cancer chemotherapeutics. However, there are limitations to their clinical application due to current challenges in their preparation techniques. Intriguingly, there is a recent drive towards the use of engineered synthetic EVs for the delivery of chemotherapeutics and RNA interference therapy (RNAi), as they show the promise of overcoming the obstacles in the treatment of OC patients. This review discusses the therapeutic application of EVs in OC and elucidates the potential use of engineered EV-mimetic nanoparticles as a delivery vehicle for RNAi therapy and other chemotherapeutics, which would potentially improve clinical outcomes of OC patients.

show abstract

Alternative tumor markers in the diagnosis of ovarian cancer

Cited by 8 publications

References 23 publications

An overview about mitochondrial DNA mutations in ovarian cancer

An overview about mitochondrial DNA mutations in ovarian cancer

Mig-7 expression and vasculogenic mimicry in malignant ovarian tumors

Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer

Contact Info

Product

Resources

About